Glenmark Life Sciences sets Indian IPO rolling

By Jonathan Breen
19 Apr 2021

India’s Glenmark Life Sciences, a pharmaceutical ingredients maker, has filed draft paperwork for an IPO of new and existing shares.

The company, a wholly-owned subsidiary of Glenmark Pharmaceuticals, plans to issue Rp11.6bn ($154.9m) of equity for the listing, while its parent will sell 7.3m secondary shares through an offer-for-sale (OFS).

Kotak Mahindra Capital is leading the IPO syndicate, which includes global co-ordinators Bank of America and Goldman Sachs, ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial